Libre Pathology - Recent changes [en]

Signet ring cell-like adenocarcinoma of the prostate

Michael — Mon, 21 Sep 2026 21:07:07 GMT

← Older revision		Revision as of 21:07, 21 September 2026
(3 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	'''Signet ring cell carcinoma of the prostate'''~~, also~~ '''prostatic signet ring cell carcinoma''', ~~is a rare aggressive form~~ of ~~[[prostate cancer]]~~.		'''Signet ring cell-like adenocarcinoma of the prostate''' is a rare aggressive form of [[prostate cancer]].

			It is also known as '''signet ring cell carcinoma of the prostate''' and '''prostatic signet ring cell carcinoma'''.

			The term "signet ring cell-like" is preferred over "signet ring cell", as per the WHO Blue Book of 2022, as the cells are often mucin negative.<ref name=pmid38929494/><ref name=WHOGU2022>{{Ref WHOGU2022\|209}}</ref>

	==General==		==General==

Signet ring cell carcinoma of the prostate

Michael — Mon, 21 Sep 2026 21:01:13 GMT

Michael moved page Signet ring cell carcinoma of the prostate to Signet ring cell-like adenocarcinoma of the prostate preferred name in WHO 5th edition

← Older revision		Revision as of 21:01, 21 September 2026
(5 intermediate revisions by the same user not shown)
Line 7:		Line 7:
	==Microscopic==		==Microscopic==
	Features:		Features:
	*Signet ring cells - ~~see ''[[basics]]'' article~~.		*Signet ring cells.
			**Large cytoplasmic vacuole, peripherical nucleus with a crescent shape.<ref name=pmid38929494>{{cite journal \| authors = Sakalauskaite M, Garnelyte A, Civilka I, Dulskas A, Kincius M, Patasius A \| title = Prostate Adenocarcinoma with Signet-Ring Cells and Features of Mucin: A Clinical Case and Literature Review \| journal = Medicina (Kaunas) \| volume = 60 \| issue = 6 \| date = May 2024 \| pmid = 38929494 \| pmc = 11205309 \| doi = 10.3390/medicina60060877}}</ref>
			*+/-Conventional prostatic carcinoma.

	DDx:		DDx:
	*Acinar adenocarcinoma - Gleason pattern 4 with very small glands.		*Acinar adenocarcinoma - Gleason pattern 4 with very small glands.
			*Metastatic [[signet ring cell carcinoma]].

	===Images===		===Images===
Line 20:		Line 23:
	==Stains==		==Stains==
	*Alcian blue-PAS stain +ve.		*Alcian blue-PAS stain +ve.
	*[[PAS stain\|PAS]] -- 50% of cases +ve.<ref name=pmid21123640/>		*[[PAS stain\|PAS]] - 50% of cases +ve.<ref name=pmid21123640/>
	*[[Alcian blue stain\|Alcian blue]] -- 44% of cases +ve.<ref name=pmid21123640/>		*[[Alcian blue stain\|Alcian blue]] - 44% of cases +ve.<ref name=pmid21123640/>

			Note:
			*May be mucin stain -ve.

			==IHC==
			*PSAP +ve.<ref name=pmid21123640/>
			*PSA +ve.
			*CEA -ve.

			Note:
			*If prostate stains (PSAP, PSA, NKX3.1) are negative, a GI primary should be excluded. Clinical correlation may be required.

	==See also==		==See also==
Line 28:		Line 41:

	==References==		==References==
	{{Reflist\|2}}		{{Reflist\|1}}

	[[Category:Diagnosis]]		[[Category:Diagnosis]]
	[[Category:Prostate carcinoma]]		[[Category:Prostate carcinoma]]

Prostate cancer

Michael — Mon, 21 Sep 2026 20:39:30 GMT

Prostatic signet ring cell carcinoma: split out

@@ Line 691: / Line 691: @@
 ==Prostatic signet ring cell carcinoma==
-{{Main|Signet ring cell carcinoma}}
+{{Main|Prostatic signet ring cell carcinoma}}
 ==Sarcomatoid carcinoma of the prostate==

Signet ring cell carcinoma of the prostate

Michael — Mon, 21 Sep 2026 20:38:59 GMT

← Older revision		Revision as of 20:38, 21 September 2026
Line 1:		Line 1:
	'''Signet ring cell carcinoma of the prostate''' is a rare aggressive form of [[prostate cancer]].		'''Signet ring cell carcinoma of the prostate''', also '''prostatic signet ring cell carcinoma''', is a rare aggressive form of [[prostate cancer]].

	==General==		==General==

Prostatic signet ring cell carcinoma

Michael — Mon, 21 Sep 2026 20:38:28 GMT

Changed redirect target from Prostate cancer#Prostatic signet ring cell carcinoma to Signet ring cell carcinoma of the prostate

← Older revision		Revision as of 20:38, 21 September 2026
Line 1:		Line 1:
	#redirect [[~~Prostate_cancer#Prostatic_signet_ring_cell_carcinoma~~]]		#redirect [[Signet ring cell carcinoma of the prostate]]

Signet ring cell carcinoma of the prostate

Michael — Mon, 21 Sep 2026 20:36:57 GMT

@@ Line 1: / Line 1: @@
 '''Signet ring cell carcinoma of the prostate''' is a rare aggressive form of [[prostate cancer]].
 ==See also==
-*[[Prostate Cancer]].
+*[[Prostate cancer]].
 ==References==

Signet ring cell carcinoma of the prostate

Michael — Mon, 21 Sep 2026 20:35:51 GMT

Created page with "'''Signet ring cell carcinoma of the prostate''' is a rare aggressive form of prostate cancer. ==See also== *Prostate Cancer. ==References== {{Reflist|2}} Category:Diagnosis Category:Prostate carcinoma"

New page

'''Signet ring cell carcinoma of the prostate''' is a rare aggressive form of [[prostate cancer]].

==See also==
*[[Prostate Cancer]].

==References==
{{Reflist|2}}

[[Category:Diagnosis]]
[[Category:Prostate carcinoma]]

Thoracic SMARCA4-deficient undifferentiated tumour

Michael — Wed, 09 Sep 2026 18:36:06 GMT

General

← Older revision		Revision as of 18:36, 9 September 2026
(One intermediate revision by the same user not shown)
Line 4:		Line 4:
	*It was debated whether it is a poorly differentiated [[carcinoma]] or a [[sarcoma]].<ref name=pmid31751681>{{cite journal \|authors=Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD \|title=SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas \|journal=J Thorac Oncol \|volume=15 \|issue=2 \|pages=231–247 \|date=February 2020 \|pmid=31751681 \|pmc=7556987 \|doi=10.1016/j.jtho.2019.10.023 \|url=}}</ref>		*It was debated whether it is a poorly differentiated [[carcinoma]] or a [[sarcoma]].<ref name=pmid31751681>{{cite journal \|authors=Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD \|title=SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas \|journal=J Thorac Oncol \|volume=15 \|issue=2 \|pages=231–247 \|date=February 2020 \|pmid=31751681 \|pmc=7556987 \|doi=10.1016/j.jtho.2019.10.023 \|url=}}</ref>
	*WHO recognized entity as of 2021.<ref name=pmid38306886>{{cite journal \|vauthors=Zhou P, Fu Y, Tang Y, Jiang L, Wang W \|title=Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy \|journal=Lung Cancer \|volume=189 \|issue= \|pages=107471 \|date=March 2024 \|pmid=38306886 \|doi=10.1016/j.lungcan.2024.107471 \|url=}}</ref>		*WHO recognized entity as of 2021.<ref name=pmid38306886>{{cite journal \|vauthors=Zhou P, Fu Y, Tang Y, Jiang L, Wang W \|title=Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy \|journal=Lung Cancer \|volume=189 \|issue= \|pages=107471 \|date=March 2024 \|pmid=38306886 \|doi=10.1016/j.lungcan.2024.107471 \|url=}}</ref>
			*Strong association with [[smoking]].<ref>{{cite journal \|authors=Kim JH, Woo JH, Lim CY, An T, Han J, Chung MJ, Cha YK \|title=SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features \|journal=J Thorac Dis \|volume=16 \|issue=3 \|pages=1753–1764 \|date=March 2024 \|pmid=38617754 \|pmc=11009581 \|doi=10.21037/jtd-23-1606 \|url=}}</ref>

	==Gross==		==Gross==
Line 15:		Line 16:

	DDx:		DDx:
			*[[SMARCA4-deficient non-small cell lung carcinoma]].
	*Large cell [[Lymphoma]]s.		*Large cell [[Lymphoma]]s.
	*[[Small cell carcinoma of the lung]].		*[[Small cell carcinoma of the lung]].

SMARCA4-deficient non-small cell lung carcinoma

Michael — Wed, 09 Sep 2026 18:25:02 GMT

redirect

New page

#redirect [[SMARCA4-deficient non-small cell carcinoma of the lung]]

Thoracic SMARCA4-deficient undifferentiated tumour

Michael — Wed, 09 Sep 2026 18:18:42 GMT

← Older revision		Revision as of 18:18, 9 September 2026
(One intermediate revision by the same user not shown)
Line 4:		Line 4:
	*It was debated whether it is a poorly differentiated [[carcinoma]] or a [[sarcoma]].<ref name=pmid31751681>{{cite journal \|authors=Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD \|title=SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas \|journal=J Thorac Oncol \|volume=15 \|issue=2 \|pages=231–247 \|date=February 2020 \|pmid=31751681 \|pmc=7556987 \|doi=10.1016/j.jtho.2019.10.023 \|url=}}</ref>		*It was debated whether it is a poorly differentiated [[carcinoma]] or a [[sarcoma]].<ref name=pmid31751681>{{cite journal \|authors=Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD \|title=SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas \|journal=J Thorac Oncol \|volume=15 \|issue=2 \|pages=231–247 \|date=February 2020 \|pmid=31751681 \|pmc=7556987 \|doi=10.1016/j.jtho.2019.10.023 \|url=}}</ref>
	*WHO recognized entity as of 2021.<ref name=pmid38306886>{{cite journal \|vauthors=Zhou P, Fu Y, Tang Y, Jiang L, Wang W \|title=Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy \|journal=Lung Cancer \|volume=189 \|issue= \|pages=107471 \|date=March 2024 \|pmid=38306886 \|doi=10.1016/j.lungcan.2024.107471 \|url=}}</ref>		*WHO recognized entity as of 2021.<ref name=pmid38306886>{{cite journal \|vauthors=Zhou P, Fu Y, Tang Y, Jiang L, Wang W \|title=Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy \|journal=Lung Cancer \|volume=189 \|issue= \|pages=107471 \|date=March 2024 \|pmid=38306886 \|doi=10.1016/j.lungcan.2024.107471 \|url=}}</ref>

			==Gross==
			*Central location.
			**Classically, [[SMARCA4-deficient non-small cell lung carcinoma]] is peripheral.<ref>{{cite journal \|authors=Kim JH, Woo JH, Lim CY, An T, Han J, Chung MJ, Cha YK \|title=SMARCA4-deficient non-small cell lung carcinoma: clinicodemographic, computed tomography, and positron emission tomography-computed tomography features \|journal=J Thorac Dis \|volume=16 \|issue=3 \|pages=1753–1764 \|date=March 2024 \|pmid=38617754 \|pmc=11009581 \|doi=10.21037/jtd-23-1606 \|url=}}</ref>

	==Microscopic==		==Microscopic==
Line 21:		Line 25:
	*Synaptophysin +ve.		*Synaptophysin +ve.
	*Chromogranin -ve.		*Chromogranin -ve.
			*SALL4 +ve.<ref name=pmid41454764>{{cite journal \|authors=Das S, Mishra P, Ahlawat S \|title=Clinicopathological and molecular perspectives on thoracic SMARCA4-deficient undifferentiated tumors and SMARCA4-deficient non-small cell lung carcinomas \|journal=Pathologica \|volume=117 \|issue=5 \|pages=455–467 \|date=December 2025 \|pmid=41454764 \|pmc=12743361 \|doi=10.32074/1591-951X-1272 \|url=}}</ref>
			*SOX2 +ve.<ref name=pmid41454764/>

	==See also==		==See also==

Sensitive

Michael — Tue, 08 Sep 2026 20:12:13 GMT

redirect

New page

#redirect [[Sensitivity and specificity]]

TRPS1

Michael — Tue, 08 Sep 2026 20:10:02 GMT

create

New page

'''TRPS1''' ('''Trichorhinophalangeal syndrome 1''') is an [[immunostain]] that is [[sensitive]] for [[breast cancer]].<ref>{{cite journal |authors=Lennartz M, Löhr N, Höflmayer D, Dwertmann Rico S, von Bargen C, Kind S, Reiswich V, Viehweger F, Lutz F, Bertram V, Fraune C, Gorbokon N, Weidemann S, Blessin NC, Hube-Magg C, Menz A, Schlichter R, Krech T, Hinsch A, Burandt E, Sauter G, Simon R, Kluth M, Marx AH, Lebok P, Dum D, Minner S, Jacobsen F, Clauditz TS, Bernreuther C, Steurer S |title=TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities |journal=Am J Surg Pathol |volume=48 |issue=6 |pages=637–651 |date=June 2024 |pmid=38647255 |pmc=11093513 |doi=10.1097/PAS.0000000000002213 |url=}}</ref>

==See also==
*[[BRST2]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]

Head and neck cytopathology

Michael — Tue, 08 Sep 2026 13:23:37 GMT

touch

← Older revision		Revision as of 13:23, 8 September 2026
(One intermediate revision by the same user not shown)
(No difference)

Phyllodes tumour

Michael — Tue, 01 Sep 2026 20:54:10 GMT

IHC

← Older revision		Revision as of 20:54, 1 September 2026
(2 intermediate revisions by the same user not shown)
Line 129:		Line 129:
	* † Stromal overgrowth = epithelial elements absent in one low power field (LPF), defined as x40;<ref name=pmid17932112>{{cite journal \|author=Taira N, Takabatake D, Aogi K, ''et al'' \|title=Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin \|journal=Jpn. J. Clin. Oncol. \|volume=37 \|issue=10 \|pages=730-6 \|year=2007 \|month=October \|pmid=17932112 \|doi=10.1093/jjco/hym099 \|url=http://jjco.oxfordjournals.org/cgi/reprint/37/10/730}}</ref> ''LPF'' is not adequately defined - see [[LPFitis]].		* † Stromal overgrowth = epithelial elements absent in one low power field (LPF), defined as x40;<ref name=pmid17932112>{{cite journal \|author=Taira N, Takabatake D, Aogi K, ''et al'' \|title=Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin \|journal=Jpn. J. Clin. Oncol. \|volume=37 \|issue=10 \|pages=730-6 \|year=2007 \|month=October \|pmid=17932112 \|doi=10.1093/jjco/hym099 \|url=http://jjco.oxfordjournals.org/cgi/reprint/37/10/730}}</ref> ''LPF'' is not adequately defined - see [[LPFitis]].
	* ‡ ''HPF'' is not adequately defined - see [[HPFitis]].		* ‡ ''HPF'' is not adequately defined - see [[HPFitis]].

			==IHC==
			Epithelial component:
			*CK7 +ve.
			*ER.
			*PR.
			Stromal cells:<ref name=pmid14608534>{{cite journal \|authors=Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO \|title=An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast \|journal=Hum Pathol \|volume=34 \|issue=10 \|pages=1009–15 \|date=October 2003 \|pmid=14608534 \|doi=10.1053/s0046-8177(03)00414-3 \|url=}}</ref>
			*CD34 +ve.
			*BCL2 +ve.
			*CK -ve.
			*GATA-3 -ve.<ref name=pmid23375642>{{cite journal \|authors=Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P \|title=GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas \|journal=Hum Pathol \|volume=44 \|issue=7 \|pages=1341–9 \|date=July 2013 \|pmid=23375642 \|pmc=3991123 \|doi=10.1016/j.humpath.2012.11.003 \|url=}}</ref>

	==Sign out==		==Sign out==

Clear cell renal cell carcinoma

Michael — Tue, 01 Sep 2026 20:23:02 GMT

IHC

← Older revision		Revision as of 20:23, 1 September 2026
Line 134:		Line 134:

	==IHC==		==IHC==
			*CAIX (also CA9) +ve (47/59 cases ~ 94%).<ref name=pmid36340463>{{cite journal \|authors=Yousef A, Kim SS, Krizova A \|title=CAIX Immunostaining in Non-neoplastic Renal Diseases \|journal=Cancer Diagn Progn \|volume=2 \|issue=6 \|pages=661–667 \|date=2022 \|pmid=36340463 \|pmc=9628162 \|doi=10.21873/cdp.10157 \|url=}}</ref>
	*CD10 +ve.		*CD10 +ve.
	*Vimentin +ve.		*Vimentin +ve.
Line 141:		Line 142:
	*Glut-1 >85% of CCRCC (membranous pattern).<ref name=pmid17638658>{{Cite journal \| last1 = Ozcan \| first1 = A. \| last2 = Shen \| first2 = SS. \| last3 = Zhai \| first3 = QJ. \| last4 = Truong \| first4 = LD. \| title = Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. \| journal = Am J Clin Pathol \| volume = 128 \| issue = 2 \| pages = 245-54 \| month = Aug \| year = 2007 \| doi = 10.1309/HV6NJVRQKK4QHM9F \| PMID = 17638658 }}</ref>		*Glut-1 >85% of CCRCC (membranous pattern).<ref name=pmid17638658>{{Cite journal \| last1 = Ozcan \| first1 = A. \| last2 = Shen \| first2 = SS. \| last3 = Zhai \| first3 = QJ. \| last4 = Truong \| first4 = LD. \| title = Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. \| journal = Am J Clin Pathol \| volume = 128 \| issue = 2 \| pages = 245-54 \| month = Aug \| year = 2007 \| doi = 10.1309/HV6NJVRQKK4QHM9F \| PMID = 17638658 }}</ref>
	*E-cadherin +ve - usually weak, often -ve in higher stage tumours.<ref name=pmid23939157>{{Cite journal \| last1 = Hu \| first1 = H. \| last2 = Chen \| first2 = JW. \| last3 = Xu \| first3 = KX. \| last4 = Wang \| first4 = D. \| last5 = Wang \| first5 = Y. \| last6 = Wang \| first6 = GW. \| last7 = Zhang \| first7 = SY. \| last8 = Wang \| first8 = XF. \| title = [Expressions of CMTM8 and E-cadherin in primary and metastatic clear cell renal cell carcinoma]. \| journal = Beijing Da Xue Xue Bao \| volume = 45 \| issue = 4 \| pages = 537-41 \| month = Aug \| year = 2013 \| doi = \| PMID = 23939157 }}</ref>		*E-cadherin +ve - usually weak, often -ve in higher stage tumours.<ref name=pmid23939157>{{Cite journal \| last1 = Hu \| first1 = H. \| last2 = Chen \| first2 = JW. \| last3 = Xu \| first3 = KX. \| last4 = Wang \| first4 = D. \| last5 = Wang \| first5 = Y. \| last6 = Wang \| first6 = GW. \| last7 = Zhang \| first7 = SY. \| last8 = Wang \| first8 = XF. \| title = [Expressions of CMTM8 and E-cadherin in primary and metastatic clear cell renal cell carcinoma]. \| journal = Beijing Da Xue Xue Bao \| volume = 45 \| issue = 4 \| pages = 537-41 \| month = Aug \| year = 2013 \| doi = \| PMID = 23939157 }}</ref>
	*CAIX (also CA9) +ve.

	A panel to confirm the diagnosis:		A panel to confirm the diagnosis:
	*CK7 (-ve), CD10 (+ve), PAX8 (+ve), vimentin (+ve).		*CAIX (+ve), CK7 (-ve), CD10 (+ve), PAX8 (+ve), vimentin (+ve).

	===CCRCC versus [[chromophobe RCC]]===		===CCRCC versus [[chromophobe RCC]]===

Mitrofanoff tract

Michael — Tue, 01 Sep 2026 18:25:40 GMT

← Older revision		Revision as of 18:25, 1 September 2026
(One intermediate revision by the same user not shown)
Line 1:		Line 1:
	'''Mitrofanoff tract''' a surgically created conduit for self-catherization, typically constructed from the [[vermiform appendix]].		'''Mitrofanoff tract''' a surgically created conduit for self-catherization, typically constructed from the [[vermiform appendix]].<ref>{{cite journal \|author=Mitrofanoff P \|title=[Trans-appendicular continent cystostomy in the management of the neurogenic bladder] \|language=fr \|journal= Chirurgie Pédiatrique\|volume=21 \|issue=4 \|pages=297–305 \|year=1980 \|pmid=7408090 }}</ref>

			==See also==
			*[[Vermiform appendix]].

			==References==
			{{Reflist\|1}}

	[[Category:Genitourinary pathology]]		[[Category:Genitourinary pathology]]

Mitrofanoff

Michael — Tue, 01 Sep 2026 18:21:55 GMT

Michael moved page Mitrofanoff to Mitrofanoff tract

← Older revision		Revision as of 18:21, 1 September 2026
(2 intermediate revisions by the same user not shown)
Line 1:		Line 1:
	'''Mitrofanoff''' a surgically ~~create~~ conduit for self-catherization constructed from the [[vermiform appendix]].		'''Mitrofanoff tract''' a surgically created conduit for self-catherization, typically constructed from the [[vermiform appendix]].

			[[Category:Genitourinary pathology]]



	[[Category:~~Uropathology~~]]

Mitrofanoff

Michael — Tue, 01 Sep 2026 18:15:41 GMT

Created page with "'''Mitrofanoff''' a surgically create conduit for self-catherization constructed from the vermiform appendix. Category:Uropathology"

New page

'''Mitrofanoff''' a surgically create conduit for self-catherization constructed from the [[vermiform appendix]].

[[Category:Uropathology]]

Cholelithiasis

Michael — Sun, 30 Aug 2026 01:28:33 GMT

touch

← Older revision		Revision as of 01:28, 30 August 2026
Line 3:		Line 3:
	\| Image = Gallensteine_2006_03_28.JPG		\| Image = Gallensteine_2006_03_28.JPG
	\| Width =		\| Width =
	\| Caption = Yellow gallstones. (WC)		\| Caption = Yellow gallstones. (WC)
	\| Synonyms =		\| Synonyms =
	\| Micro =		\| Micro =

Ameloblastoma

Michael — Sun, 30 Aug 2026 01:26:06 GMT

touch

← Older revision		Revision as of 01:26, 30 August 2026
Line 3:		Line 3:
	\| Image = Ameloblastoma - high mag.jpg		\| Image = Ameloblastoma - high mag.jpg
	\| Width =		\| Width =
	\| Caption = Ameloblastoma. [[H&E stain]].		\| Caption = Ameloblastoma. [[H&E stain]].
	\| Synonyms =		\| Synonyms =
	\| Micro = stellate reticulum (star-shaped cells), tall columnar cells that have palisaded nuclei with reverse polarization, subnuclear vacuolization, +/-giant cells, +/-subepithelial hyalinization (eosinophilic acellular amorphous material)		\| Micro = stellate reticulum (star-shaped cells), tall columnar cells that have palisaded nuclei with reverse polarization, subnuclear vacuolization, +/-giant cells, +/-subepithelial hyalinization (eosinophilic acellular amorphous material)

Other CNS embryonal tumours

Michael — Sun, 30 Aug 2026 01:18:48 GMT

+ref list

← Older revision		Revision as of 01:18, 30 August 2026
Line 90:		Line 90:
	* H3F3A G34-mutated [[Glioblastoma]]		* H3F3A G34-mutated [[Glioblastoma]]
	* Metastasis of [[Ewing sarcoma]]		* Metastasis of [[Ewing sarcoma]]

			==References==
			{{Reflist\|2}}

	[[Category:Neuropathology]]		[[Category:Neuropathology]]
	[[Category:Neuropathology tumours]]		[[Category:Neuropathology tumours]]

Complex endometrial hyperplasia

Michael — Sun, 30 Aug 2026 01:13:36 GMT

touch

← Older revision		Revision as of 01:13, 30 August 2026
Line 3:		Line 3:
	\| Image = Complex endometrial hyperplasia -- intermed mag.jpg		\| Image = Complex endometrial hyperplasia -- intermed mag.jpg
	\| Width =		\| Width =
	\| Caption = Complex endometrial hyperplasia. [[H&E stain]].		\| Caption = Complex endometrial hyperplasia. [[H&E stain]].
	\| Micro = increase in size & number of glands + irregular shape, nuclear pseudostratification, nuclear enlargement, mitoses common, +/-nuclear atypia (round nuclei ~ 2-3x the size of a lymphocyte, grey/translucent chromatin, nucleoli)		\| Micro = increase in size & number of glands + irregular shape, nuclear pseudostratification, nuclear enlargement, mitoses common, +/-nuclear atypia (round nuclei ~ 2-3x the size of a lymphocyte, grey/translucent chromatin, nucleoli)
	\| Subtypes = CEH [[NOS]] (CEH without atypia), CEH with atypia		\| Subtypes = CEH [[NOS]] (CEH without atypia), CEH with atypia

Colitis cystica profunda

Michael — Fri, 28 Aug 2026 17:56:10 GMT

Microscopic

← Older revision		Revision as of 17:56, 28 August 2026
Line 44:		Line 44:
	==Microscopic==		==Microscopic==
	Features:		Features:
	*Mucin filled cysts in the submucosa<ref name=pmid16018526/><ref name=pmid18563984/> or deeper.<ref name=pmid21212765/>		*Mucin filled cysts in the submucosa<ref name=pmid16018526/><ref name=pmid18563984/> or deeper.<ref name=pmid21212765>{{cite journal \|authors=Qayed E, Srinivasan S, Wehbi M \|title=A case of colitis cystica profunda in association with diverticulitis \|journal=Am J Gastroenterol \|volume=106 \|issue=1 \|pages=172–3 \|date=January 2011 \|pmid=21212765 \|doi=10.1038/ajg.2010.374 \|url=}}</ref>
	*+/-Inflammation.		*+/-Inflammation.